Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

WCLC 2022 | Combining radiotherapy with novel agents in NSCLC

Gerard M. Walls, MB, MRCP, MSc, FRCR, Queen’s University Belfast, Belfast, UK, provides the rationale behind combining novel agents with conventional radiotherapy in non-small cell lung cancer (NSCLC), as investigated in the Phase I CONCORDE (NCT04550104) trial. Many patients are unable to tolerate chemotherapy concurrently with radiotherapy, however, novel radiosensitizing agents could improve the effectiveness of radiotherapy so chemotherapy can be avoided. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.